Last reviewed 2026-05-31 · How we verify

Anthrex (PROQUAZONE)

Phase 2 active Small molecule ✓ Verified May 2026

Anthrex (generic name: PROQUAZONE) is a proquazone drug. It is currently in Phase 2 development.

Proquazone works by directly interacting with the Epidermal Growth Factor Receptor (EGFR) to potentially inhibit its activity.

Anthrex, also known as Proquazone, is a small molecule. It has multiple synonyms, including 43-715 and Proquazone.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PROQUAZONE
Drug class	proquazone
Target	Epidermal growth factor receptor, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your cells have locks on them, and the Epidermal Growth Factor Receptor is a key that fits into those locks. Proquazone is a small molecule that tries to block the key from fitting into the lock, which could help slow down the growth of certain cells. This is a simplified explanation of how it works at a molecular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Anthrex CI brief — competitive landscape report
Anthrex updates RSS · CI watch RSS

Frequently asked questions about Anthrex

What is Anthrex?

Anthrex (PROQUAZONE) is a proquazone drug.

How does Anthrex work?

Proquazone works by directly interacting with the Epidermal Growth Factor Receptor (EGFR) to potentially inhibit its activity.

What is the generic name of Anthrex?

PROQUAZONE is the generic (nonproprietary) name of Anthrex.

What drug class is Anthrex in?

Anthrex belongs to the proquazone class. See all proquazone drugs at /class/proquazone.

What development phase is Anthrex in?

Anthrex is in Phase 2.

What does Anthrex target?

Anthrex targets Epidermal growth factor receptor, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2 and is a proquazone.

Drug class: All proquazone drugs
Target: All drugs targeting Epidermal growth factor receptor, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing